Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, open-label study to assess copper and molybdenum balance in participants with Wilson disease treated with ALXN1840

Next Previous
Trial Profile

A Phase 2, open-label study to assess copper and molybdenum balance in participants with Wilson disease treated with ALXN1840

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tiomolibdate choline (Primary)
  • Indications Hepatolenticular degeneration
  • Focus Therapeutic Use
  • Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

  • 13 Nov 2025 According to Monopar Therapeutics media release,On September 14-15, 2025, the Company presented new data on the long-term neurological efficacy and safety of ALXN1840 (tiomolybdate choline) at the 150th American Neurological Association (ANA) Annual Meeting.
  • 09 Nov 2025 According to Monopar Therapeutics media release, data from this study presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025, taking place in Washington, D.C., from November 7-11, 2025.
  • 15 Oct 2025 According to Monopar Therapeutics media release, the company announced that its abstract on the Phase 2 ALXN1840-WD-204 copper balance study has been selected for an oral presentation at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting 2025, taking place in Washington, D.C., from November 7-11, 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top